Tripartite Therapeutics, Inc.
TTPEX:79207.90
TWD
-0.17
(-2.11%)
Tripartite Therapeutics, Inc.
TPEX:7920
(Taipei Exchange)
Recent
price
7.90
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Tripartite Therapeutics, Inc. is a biotechnology company that engages in the research, development, and out-licensing of proprietary targeted drug delivery platforms and next-generation antibody-drug conjugates for oncology, immunology, and metabolic disease applications. The company develops and provides biopharmaceutical solutions comprising OmniLink, a universal hydrophilic oligosaccharide linker platform designed to improve drug stability, aqueous solubility, and drug-to-antibody ratios while mitigating systemic toxicity; Polarpeutic, a proprietary hydrophilic payload modification technology that enhances payload water solubility while preserving antitumor potency; Trastuzumab-based Antibody Polar Drug Conjugates (APDCs), preclinical-stage targeted therapeutic candidates engineered for the treatment of HER2-positive metastatic breast cancer; Toll-like receptor (TLR) agonist-conjugated immuno-oncology candidates, designed to activate immune responses locally within tumor microenvironments for gastric and other solid tumors; Dual-Payload ADCs, engineered to deliver multiple synergistic antineoplastic mechanisms to overcome drug resistance; and technology platform out-licensing and co-development services for international biotechnology and pharmaceutical partners. Founded in 2009, Tripartite Therapeutics, Inc. is headquartered in Taipei, Taiwan. In recent developments, the company listed its shares on the Emerging Stock Board of the Taipei Exchange (TPEx: 7920) in May 2026, marking a key capital markets milestone to fund clinical advancements. In addition, the company expanded the therapeutic scope of its OmniLink and Polarpeutic platforms from single-agent oncology conjugates into dual-payload ADC modalities, metabolic diseases, and targeted vaccines, while actively pursuing international commercial partnerships and licensing collaborations across North America and Asia.